VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Algenpantucel-L
Vaccine Information
  • Vaccine Name: Algenpantucel-L
  • Vaccine Ontology ID: VO_0007216
  • Type: Other
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • CEACAM5 (CEA) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • MSLN gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Preparation: Algenpantucel-L is a whole-cell vaccine with a combination of 2 irradiated allogeneic PC cells lines (HAPa-1, HAPa-2) genetically engineered by retrovirus transduction to express the murine enzyme α(1,3)-galactosyltransferase (αGT) (McCormick et al., 2016).
  • Description: A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells. (NCIT_C61082).

    Phase II clinical trial data has been encouraging, particularly for patients who demonstrated humoral immunologic responses for pancreatic adenocarcinoma patients.(Coveler et al., 2016)
References
Coveler et al., 2016: Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy. 2016; 8(2); 117-125. [PubMed: 26787078].
McCormick et al., 2016: McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Human vaccines & immunotherapeutics. 2016; 12(3); 563-575. [PubMed: 26619245].
NCIT_C61082: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61082]
Allogeneic Cellular Vaccine 1650-G
Vaccine Information
  • Vaccine Name: Allogeneic Cellular Vaccine 1650-G
  • Vaccine Ontology ID: VO_0007219
  • Type: Other
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: ERBB2
  • CEACAM5 (CEA) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • WT1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • MAGEA2 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Preparation: 1650-G comprises an apoptosed and lethally irradiated tumor cell allogeneic line and GMCSF (Berlex Inc., Richmond, CA). The lung tumor cell line 1650 is known to overexpress Her-2/neu, carcinoembryonic antigen, Mage 2, WT-1, survivin, and New York esophageal squamous cell carcinoma 1 antigen (Hirschowitz et al., 2011).
    The vaccine (delivered intradermally) is composed of four class II restricted HER-2/neu peptides plus 125 μg GM-CSF (Hirschowitz et al., 2006).
    DC vaccines were generated from CD14+ precursors, pulsed with apoptotic bodies of an allogeneic NSCLC cell line that overexpressed Her2/neu, CEA, WT1, Mage2, and survivin (Hirschowitz et al., 2004).
  • Description: A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs. (NCIT_C119759).
References
Hirschowitz et al., 2004: Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(14); 2808-2815. [PubMed: 15254048].
Hirschowitz et al., 2006: Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006; 1(1); 93-104. [PubMed: 17409835].
Hirschowitz et al., 2011: Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6(1); 169-173. [PubMed: 21150468].
NCIT_C119759: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119759]
hTERT Vaccine V934/V935
Vaccine Information
  • Vaccine Name: hTERT Vaccine V934/V935
  • Vaccine Ontology ID: VO_0007404
  • Type: Other
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • TERT gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Description: NULL
References
 
KLH-Lymphoma Ig Vaccine
Vaccine Information
  • Vaccine Name: KLH-Lymphoma Ig Vaccine
  • Vaccine Ontology ID: VO_0007470
  • Type: Other
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Adjuvant: GM-CSF vaccine adjuvant
  • Description: A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth. (NCI04) (NCIT_C2771).
References
NCIT_C2771: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2771]